Navigation Links
Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Date:1/6/2009

RESEARCH TRIANGLE PARK, N.C., Jan. 6 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers. This study supports the further development of the drug for multiple dsDNA infections. The Company has initiated the first Phase II multi-dose clinical trial in patients.

"The safety and high oral availability demonstrated by CMX001 in the Phase I trial has exceeded our original expectations," said Dr. George Painter, Chimerix President and CEO. "We believe that CMX001 has potential for prevention and treatment of many serious and potentially fatal infections such as smallpox, cytomegalovirus, BK virus and adenovirus."

The Phase I study of CMX001 was a blinded, randomized, placebo-controlled study that evaluated the safety and pharmacokinetics of orally administered CMX001 in healthy volunteers. The study found CMX001 to be well tolerated at all doses in 84 healthy volunteers.

The first Phase II trial will study the effects of multiple doses of CMX001 given to stem cell and kidney transplant recipients with BK viruria, a condition which may eventually lead to loss of the kidney graft, or to uncontrolled bleeding in the bladder. Further studies are planned to explore the ability of CMX001 to prevent cytomegalovirus disease, a viral disease that may lead to blindness or severe gastrointestinal disease after bone marrow transplant.

CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality. A safe, orally active antiviral drug to treat smallpox infection is needed to help people who become ill after exposure to the disease or those who cannot be vaccinated. The work is partially funded by a $36.1 million grant awarded to the company by the National Institute of Allergy and Infectious Diseases.

About Chimerix

Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Carrington Completes $8 Million Financing
7. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
8. New Brunswick Scientific Completes Merger Transaction with Eppendorf
9. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
10. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
11. Optherion, Inc. Completes $37 Million Start Up Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in ... to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays ... able to offer NAT screening for blood donors under an Investigational New Drug (IND) ...
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps 2017, ... North America this May on the following dates: , ?    London, UK ... Chairman of the Learning and Performance Institute will be the opening keynote ...
(Date:4/26/2017)...  Genisphere LLC, provider of the 3DNA ┬« ... and sponsored research agreement with the University of ... overall goal of the partnership is to study ... and formulations after in vivo administration. ... as well as inflammatory responses, demonstrating various methods ...
(Date:4/25/2017)... ... 2017 , ... Franz Inc ., an early innovator ... market leader for Semantic Graph Database technology, today announced Allegro ... effective system for developing and deploying applications to solve the challenges developers face ...
Breaking Biology Technology:
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG┬┤s multi-biometrics system.   Continue ... ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric ... ... DERMALOGs Face Matching enables to match face pictures ... the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face ...
Breaking Biology News(10 mins):